01—Abstract
Summary
Summary of the 10-K filed March 29, 1996. Cited figures are marked; the original filing is the authoritative source.
Pfizer's 1995 fiscal year was a landmark year: net sales from continuing operations crossed $10.0 billiona for the first time (up 26% from $7.98 billion in 1994), and net income rose 21% to $1,572.9 million, or $2.50 per share.
Growth was driven overwhelmingly by volume (24 points of the 26% increase), with essentially no contribution from pricing (-1 point). The Health Care segment, which generated 84% of sales ($8.41 billionb, up 21%), remained the core of the business, led by a portfolio of 1990s launches: Norvasc (about $1.3 billion), Procardia XL (about $1.1 billion), Zoloft (about $1.0 billion), and Diflucan (about $880 million). The $1.5 billion acquisition of SmithKline Beecham's animal health business in January 1995 lifted Animal Health sales 101% to $1.22 billion, and the purchase also added goodwill amortization and interest costs that pushed Other deductions-net up 128%.
Margins held up: the effective tax rate rose to 32.1% from 30.0%, while SI&A fell to 38.5% of sales from 39.9%, reflecting cost discipline. Liquidity remained solid, with operating cash flow of $1.82 billionc, Aaa/AAA debt ratings, and shareholders' equity per share up to $8.90 from $7.10. Investors should weigh several risks.
The U.S. pricing environment is tightening through managed care growth, Medicaid rebates ($85 milliond in 1995), and price competition. Procardia XL faces future competition from sustained-release nifedipine generics, and the FDA advisory panel's January 1996 review of calcium channel blockers created label uncertainty for immediate-release nifedipine (Procardia). Pending U.S. legislation could phase out the Section 936 Puerto Rico tax credit, and an IRS dispute over 1987-1989 swap transactions (about $72 million plus interest, with a potential additional $86 million) and Belgian tax assessments of roughly $432 million plus interest are unresolved.
Pfizer maintains that none of these matters should have a material adverse effect. Litigation exposure includes Shiley heart valve claims, asbestos cases, a federal retail pharmacy antitrust class action (the Company's share of the settlement is $31.25 million), and a Brazilian judgment with a potential $88 million public fund payment. Looking ahead, management planned to spend about $1.7 billion on R&D in 1996, up from $1.44 billion in 1995, and it disclosed 15 new chemical entities in late-stage development.
Pending FDA filings include Zithromax indications, Zoloft for panic disorder, and tenidap for arthritis. Recent deals include the Leibinger acquisition in January 1996 and the Cortizone/Hemorid brand purchase, while the food science business was divested to Cultor for about $350 million. The company also raised its quarterly dividend 15% to $0.30 in January 1996, extending its streak of consecutive annual dividend increases to 29 years.
02—Key points
Key Highlights
- Net sales from continuing operations reached $10.02 billion, up 26% year over year, with volume driving nearly all of the growth and pricing roughly flat (-1%)
- Net income rose 21% to $1.57 billion ($2.50 per share); income from continuing operations grew 22% to $1.55 billion despite a higher effective tax rate of 32.1%
- Health Care was 84% of sales ($8.41 billion, +21%) and 95% of segment profit ($2.55 billion), anchored by Norvasc, Procardia XL, Zoloft, and Diflucan, each generating roughly $0.9–1.3 billion in annual sales
- The $1.5 billion SmithKline Beecham animal health acquisition more than doubled Animal Health sales to $1.22 billion (+101%) and is now the company's second-largest segment
- Operating efficiencies improved: SI&A expenses fell to 38.5% of sales from 39.9%, and cost of sales held at 21.6% of sales despite purchase accounting charges
- R&D spending rose 28% to $1.44 billion, with a planned increase to about $1.7 billion in 1996 and 15 new chemical entities in late-stage development
- Significant contingencies remain, including an unresolved IRS dispute, Belgian tax assessments, Shiley heart valve litigation, asbestos claims, and a federal retail pharmacy antitrust class action trial scheduled for May 1996
03—Questions
Frequently Asked Questions
How much revenue and profit growth did Pfizer deliver in 1995, and how sustainable is it?
Net sales grew 26% to $10.02 billion and net income grew 21% to $1.57 billion. Volume drove almost all of the sales growth, which included the SmithKline Beecham animal health acquisition (about 8 points excluding SBAH, at 18% organic growth per management). Organic growth of 18% is strong for a large pharmaceutical company, but it depends on continued success of recent launches and on U.S. pricing pressures that management expects to persist in 1996.
What are the main product drivers behind Pfizer's growth, and how concentrated is the portfolio?
The six major products launched in the 1990s (Norvasc, Zoloft, Diflucan, Cardura, Zithromax, and Glucotrol XL) accounted for 41% of 1995 consolidated net sales, up from 34% in 1994, and grew 48%. Norvasc grew 65% to about $1.3 billion and is the largest single product. This concentration means the company is sensitive to competition, patent timing (Procardia XL's patent runs to 2003, Zithromax's U.S. product patent to 2005), and regulatory actions affecting calcium channel blockers.
What regulatory and legal risks could materially affect Pfizer's earnings?
Key risks include potential Medicare and Medicaid reforms that could restrict access to new medicines, the proposed phase-out of the Section 936 Puerto Rico tax credit over five to ten years, and the FDA advisory panel's January 1996 recommendations on immediate-release nifedipine labeling. Litigation includes Shiley heart valve claims, asbestos cases, a federal class action by retail pharmacies alleging discrimination (Pfizer's share of the settlement is $31.25 million), and a Brazilian ruling that could require an approximately $88 million payment. Management says none of these should have a material adverse effect, but they are unquantified in several cases.
How strong is Pfizer's balance sheet and capital return to shareholders?
Pfizer's senior debt is rated Aaa by Moody's and AAA by S&P. Total assets rose to $12.73 billion and shareholders' equity to $5.51 billion ($8.90 per share, up from $7.10). Debt to total capitalization fell to 34% from 40%. Operating cash flow was $1.82 billion, though investing outflows of $2.34 billion were largely funded by commercial paper for the SBAH deal. Cash dividends rose 11% to $1.04 per share, and the company announced a 15% increase in the first-quarter 1996 dividend to $0.30.
What is the outlook for Pfizer's pipeline and upcoming commercial catalysts?
Pending FDA applications include Zithromax for lower respiratory tract infections in children, Mycobacterium avium complex, and atypical pneumonia, as well as Zoloft for panic disorder (all filed in December 1995). Zoloft for obsessive-compulsive disorder is approvable, and Zyrtec was cleared in the U.S. for allergies and urticaria. Tenidap for arthritis is under review, and the company holds U.S. and Japanese marketing rights to XOMA's E5 antibody. Pipeline success is the primary driver of future growth, and the 1996 R&D budget of about $1.7 billion signals continued commitment.
04—Continue